Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM-TMI with FluBu4 and PTCY for High-Risk AML, CML, and MDS
NCT06802315Phase 2Recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Feb 2025
- Primary completion
- Mar 2030
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, fludarabine, busulfan in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), sponsored by University of Illinois Chicago. Started Feb 2025; status: recruiting.
02
Drugs
cyclophosphamidefludarabinebusulfan
03
Conditions
acute myeloid leukemia (AML)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06802315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06802315.